GGrantIndex
← Leaderboards

Mansoor M. Amiji

University Of California At Davis

Google Scholar ↗PubMed ↗ORCID ↗
$9,305,730
Attributed
$14,462,637
Total exposure
15
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$14,462,637 · 15

By mechanism

R01$8,425,638 · 5
R21$2,419,866 · 6
U01$2,096,315 · 1
U54$1,220,966 · 2
R56$299,852 · 1

Top collaborators

Others in their field

Top investigators on “In Vitro”

Research focus

In VitroIn VivoBaseMalignant NeoplasmsEncapsulatedTumorUptakePharmaceutical PreparationsNanotechnologyTreatment EfficacyEvaluationToxic EffectCellsSurfaceBiodistributionSafetyResearch PersonnelInnovationPaclitaxelTissuesRefractoryCombined Modality TherapyCancer PatientCytotoxicity

Grant awards (49)

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer$572,502
R01 · FY2025 · CA
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer$86,583
R01 · FY2025 · CA
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer$496,381
R01 · FY2024 · CA
TGX-1214 - Combination strategy for the treatment of advanced pancreatic cancer$83,743
R01 · FY2024 · CA
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer$583,071
R01 · FY2023 · CA
Intranasal gene delivery for Alzheimer’s disease$445,124
R21 · FY2021 · AG
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors$217,282
R21 · FY2018 · CA · contact PI
Integrated Nano-Therapeutics to Overcome Tumor Plasticity and Resistance$299,852
R56 · FY2017 · CA · contact PI
Oral Gene Delivery to Improve Iron Overload Disorders$229,025
R21 · FY2017 · EB
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors$170,738
R21 · FY2017 · CA · contact PI
Oral Gene Delivery to Improve Iron Overload Disorders$190,400
R21 · FY2016 · EB
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer$523,530
R01 · FY2015 · CA
Targeted Platinates/siRNA Combination Therapy for Resistant Lung Cancer$202,928
R21 · FY2015 · CA · contact PI
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer$665,610
R01 · FY2014 · CA
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE$400,638
U01 · FY2014 · CA · contact PI
Multi-Modal Gene Therapy for Pancreatic Cancer using Targeted Nanovectors$184,882
U54 · FY2014 · CA · contact PI
Targeted Platinates/siRNA Combination Therapy for Resistant Lung Cancer$169,106
R21 · FY2014 · CA · contact PI
Education/Training and Outreach Activites$53,866
U54 · FY2014 · CA · contact PI
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer$596,489
R01 · FY2013 · CA
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE$386,926
U01 · FY2013 · CA · contact PI
Multi-Modal Gene Therapy for Pancreatic Cancer using Targeted Nanovectors$178,758
U54 · FY2013 · CA · contact PI
Education/Training and Outreach Activites$51,921
U54 · FY2013 · CA · contact PI
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer$540,181
R01 · FY2012 · CA
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE$413,032
U01 · FY2012 · CA · contact PI
Multi-Modal Gene Therapy for Pancreatic Cancer using Targeted Nanovectors$191,785
U54 · FY2012 · CA · contact PI
Education/Training and Outreach Activites$55,532
U54 · FY2012 · CA · contact PI
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer$568,797
R01 · FY2011 · CA
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE$413,032
U01 · FY2011 · CA · contact PI
ORAL GENE THERAPY WITH NiMOS FOR INFLAMMATORY BOWEL DISEASE$326,985
R01 · FY2011 · DK · contact PI
Multifunctional Nanoemulsions for Modulation of BBB Transport$234,000
R21 · FY2011 · NS · contact PI
NANO-DELIVERY OF MITOCHONDRIA-SPECIFIC CERAMIDE TO OVERCOME TUMOR DRUG RESISTANCE$196,840
R21 · FY2011 · CA · contact PI
Multi-Modal Gene Therapy for Pancreatic Cancer using Targeted Nanovectors$192,425
U54 · FY2011 · CA · contact PI
Education/Training and Outreach Activites$55,540
U54 · FY2011 · CA · contact PI
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE$482,687
U01 · FY2010 · CA · contact PI
ORAL GENE THERAPY WITH NiMOS FOR INFLAMMATORY BOWEL DISEASE$330,289
R01 · FY2010 · DK · contact PI
Multi-Modal Gene Therapy for Pancreatic Cancer using Targeted Nanovectors$199,009
U54 · FY2010 · CA · contact PI
Multifunctional Nanoemulsions for Modulation of BBB Transport$195,000
R21 · FY2010 · NS · contact PI
NANO-DELIVERY OF MITOCHONDRIA-SPECIFIC CERAMIDE TO OVERCOME TUMOR DRUG RESISTANCE$169,423
R21 · FY2010 · CA · contact PI
Education/Training and Outreach Activites$57,248
U54 · FY2010 · CA · contact PI
ORAL GENE THERAPY WITH NiMOS FOR INFLAMMATORY BOWEL DISEASE$333,625
R01 · FY2009 · DK · contact PI
NANOTHERAPEUTIC STRATEGY FOR MULTIDRUG RESISTANT TUMORS$199,385
R01 · FY2009 · CA · contact PI
NANOTHERAPEUTIC STRATEGY FOR MULTIDRUG RESISTANT TUMORS$362,876
R01 · FY2008 · CA · contact PI
ORAL GENE THERAPY WITH NiMOS FOR INFLAMMATORY BOWEL DISEASE$333,625
R01 · FY2008 · DK · contact PI
NANOTHERAPEUTIC STRATEGY FOR MULTIDRUG RESISTANT TUMORS$359,916
R01 · FY2007 · CA · contact PI
NANOTHERAPEUTIC STRATEGY FOR MULTIDRUG RESISTANT TUMORS$360,523
R01 · FY2006 · CA · contact PI
NANOTHERAPEUTIC STRATEGY FOR MULTIDRUG RESISTANT TUMORS$399,999
R01 · FY2005 · CA
LONG-CIRCULATING TUMOR-SELECTIVE DNA DELIVERY SYSTEMS$223,725
R01 · FY2005 · CA
LONG-CIRCULATING TUMOR-SELECTIVE DNA DELIVERY SYSTEMS$224,153
R01 · FY2004 · CA
LONG-CIRCULATING TUMOR-SELECTIVE DNA DELIVERY SYSTEMS$253,650
R01 · FY2003 · CA